RLYB: SEC Form 425 filed by Rallybio Corporation
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for RLYB
Across the 5 sessions after earlier RLYB headlines, the stock closed higher 3 times and lower 2 times, with a median move of 10.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | RLYB | SPY |
|---|---|---|---|
| Jun 1, 2026 | Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement | +16.7% | +0.3% |
| Mar 2, 2026 | Rallybio Corporation and Candid Therapeutics Announce Merger Agreement | +45.5% | +0.1% |
| Feb 17, 2026 | Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement | -10.2% | +0.2% |
| Feb 4, 2026 | Rallybio Announces Reverse Stock Split of Common Stock | -8.1% | -0.5% |
| Nov 6, 2025 | Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates | +2.2% | -1.1% |
Quantisnow market dataNASDAQ
RLYB
Rallybio Corporation
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for RLYB
Full RLYB profile on Quantisnow Follow RLYB and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time